FDA Enforcement and the Gray Market: What's Happening in 2026

Federal enforcement against gray-market peptide sellers is not new — the Justice Department brought its first criminal case against a large peptide compounder back in 2020. What has changed is the pace and the breadth. Since 2025 the scattered actions have become a coordinated campaign: criminal prosecutions that ended in prison sentences, dozens of warning letters to the telehealth companies and online sellers marketing compounded GLP-1s, more than a hundred civil suits from drug manufacturers, and a border alert covering imported GLP-1 ingredients. The message from federal regulators is no longer ambiguous: selling injectable peptides outside the regulated pharmaceutical system carries real legal consequences.

A timeline of enforcement

The pattern has followed a clear escalation — from civil letters to criminal prosecution to prison sentences and private lawsuits. Here are the key actions, in chronological order.

October 2020 — Tailor Made Compounding (DOJ criminal prosecution). Tailor Made Compounding LLC, a compounder in Nicholasville, Kentucky, and its owner Jeremy Delk pleaded guilty in the U.S. District Court for the Eastern District of Kentucky. The company pleaded to distributing unapproved new drugs; Delk pleaded to one count of unlicensed wholesale distribution of a prescription drug. The company agreed to forfeit $1,788,906.82, representing its 2019 sales of the products at issue — which included BPC-157, CJC-1295, ipamorelin, melanotan II, selank, and semax.^[1] This case is worth knowing about precisely because it is old: the legal theory now being used against peptide sellers was already being used successfully six years ago.

Through August 2025 — 132 Novo Nordisk lawsuits. Novo Nordisk, the manufacturer of Ozempic and Wegovy, reported filing 132 complaints across 40 states against sellers of compounded semaglutide.^[5] These are state-law claims — deceptive marketing, consumer fraud, and unfair competition — not trademark or patent suits. The distinction matters: there is no private right of action under the federal Food, Drug, and Cosmetic Act, so a manufacturer cannot sue anyone directly for violating it. It has to route through state law, which is the same structural point that explains the Lilly filings discussed below. These are civil cases rather than government enforcement, but they have created significant legal risk across the supply chain.

September 9, 2025 — 58 FDA warning letters over online GLP-1 sales. In a single day the FDA issued 58 warning letters under one subject line: unlawful sale of unapproved and misbranded drugs to U.S. consumers over the internet.^[4] The recipients were telehealth companies, online sellers, and med spas — among them Hims & Hers, Zealthy, and Remedy Meds — not compounding pharmacies. Only two compounding-pharmacy letters went out in the whole of September 2025. The theory was the sale itself: marketing and shipping unapproved drugs directly to consumers. This shifted FDA's attention from the pharmacies making compounded semaglutide and tirzepatide to the platforms selling them, and it set the pattern for the telehealth waves that followed in 2026.^[11]

December 10, 2025 — Paradigm Peptides (DOJ criminal prosecution). Paradigm Peptides, one of the most visible gray-market peptide vendors in the United States, saw its operators plead guilty in federal court. The case was brought in the Northern District of Indiana (United States v. Matthew Kawa, et al.); Kawa and co-defendant Jennifer Stechkober entered pleas on December 10, 2025.^[2] Investigators determined that many products advertised and sold as SARMs in fact contained testosterone.

February 2026 — Hims & Hers referred to the DOJ. After Hims & Hers announced a $49-per-month compounded oral semaglutide product, HHS asked the Department of Justice to investigate the company — on or about February 6, 2026 — for potentially violating federal law.^[12]

February 20, 2026 — 30 telehealth warning letters. The FDA warned 30 telehealth companies over their marketing of compounded semaglutide and tirzepatide, citing claims that implied FDA approval or equivalence to the branded drugs — a form of misbranding. The letters were issued February 20 and posted publicly on March 3, 2026.^[11]

March 6, 2026 — Peptide Sciences shutdown. Peptide Sciences, which retailer analytics firm Grips Intelligence estimated was generating roughly $7.45 million per month as of December 2025,^[10] displayed a shutdown notice on its website and stopped accepting orders. At the time, the testing service Finnrick rated its retatrutide product an "E" — the bottom of a letter-grade scale Finnrick retired in July 2026 — across 37 samples. That grade can no longer be checked at the source. Finnrick's current rating for the same product is 56% across 41 tests, with the vendor at 61% overall, as of August 15, 2026.^[6] For a detailed analysis, see our coverage of the Peptide Sciences shutdown.

June 8, 2026 — 25 more telehealth warning letters. The FDA issued another wave of 25 warning letters over the same misbranding concerns, posted the week of June 15, alongside new FDA compliance pages explaining the rules for telehealth companies that promote compounded drugs.^[11]

July 30, 2026 — Kawa sentenced to 70 months. Nearly eight months after his plea, Kawa was sentenced to 70 months — five years and ten months — plus a year of supervised release and restitution; Stechkober received 16 months.^[3] This is the most severe outcome any U.S. peptide seller has faced. We covered the case in detail in our report on the Paradigm Peptides sentencing.

August 12, 2026 — Eli Lilly sues six retatrutide sellers. Lilly filed six lawsuits in a single day over retatrutide, its unapproved investigational triple agonist. Lilly describes the defendants as compounding pharmacies, medical spas, and online sellers that "falsely claim their drugs are for 'research-use only'." Alongside the filings, Lilly publicly asked online marketplaces and payment processors to shut the sellers out.^[13] More on why the legal theory is unusual below.

August 13, 2026 — Import Alert 66-80 republished. FDA's detention-without-physical-examination alert for imported GLP-1 bulk drug substances was reissued, and the revision expanded its scope rather than merely housekeeping the Green List: it added a new product code for orforglipron, added four "Hormone N.E.C." product codes, and updated the guidance on what a manufacturer must submit to get green-listed. The alert remains the biggest structural constraint on gray-market GLP-1 API supply. It authorizes detention of all foreign-sourced GLP-1 APIs except green-listed firm/product pairs, and its product codes reach peptide APIs for prescription compounding and import entries containing the word "Retatrutide."^[15]

What did not happen this summer

Enforcement coverage tends to compound: every new action gets added to a list, and the list only ever grows. That produces a distorted picture. So here is the honest counterweight, from a direct read of FDA's own warning-letter database and import alerts through August 15, 2026.

No new FDA warning letters naming peptides, GLP-1s, or peptide sellers were issued between late June and mid-August 2026. The most recent peptide-named letter on FDA's books was issued June 17, 2026, and the most recent GLP-1 telehealth wave was issued June 8, 2026 — both before this window. FDA posts letters with a lag of one to three weeks, so this is firm for letters issued through roughly mid-July and provisional after that.

FDA's internet-seller enforcement machinery stayed busy, but it was pointed elsewhere. The one wave of "unapproved new drugs / misbranded" letters posted in July 2026 went to ketamine e-commerce sites, not peptide vendors. Same charge theory, same program, different product class.

No peptide-related firms were added to Import Alert 66-41 (unapproved new drugs promoted in the US) in the window. The in-window additions were Ayurvedic and herbal product manufacturers.

FDA issued no press release and no compounding risk alert on peptides, GLP-1s, or compounding in the entire seven-week period, including the weeks straddling the July PCAC meeting. Its most recent compounding risk alert still dates to April 2025.

None of that means the pressure is off. It means the summer's escalation came from manufacturers and foreign regulators, not from new FDA letters — which is a meaningfully different shape of risk for anyone still buying from research-use-only vendors.

The "research use only" defense is dead

For years, gray-market peptide vendors operated under a legal theory: if they labeled products "for research use only" or "not for human consumption," they were selling research chemicals rather than drugs, and therefore fell outside FDA jurisdiction.

The FDA has dismantled this argument. Under FDA's intended-use regulations, a product's intended use may be established by any relevant source — labeling, advertising, and the circumstances of distribution — not just by what the label says.^[8] When a company sells injectable peptides alongside bacteriostatic water, includes dosing calculators on its website, markets to individual consumers rather than research institutions, and ships to residential addresses, the FDA considers these unapproved drugs regardless of any disclaimer.

The Paradigm Peptides case is the clearest test of that so far. The products carried research-use-only disclaimers; the government charged the sales as introducing unapproved drugs into interstate commerce anyway, and both defendants pleaded guilty.^[2][3] Be precise about what that does and does not establish: a guilty plea is a defendant's admission, not a court ruling on whether the disclaimer works. What it shows is that the disclaimer did not stop the charges from sticking, or the sentence from being imposed.

This matters because the research-use-only model was the legal foundation on which the entire gray-market peptide industry was built. Every remaining vendor operating under the same model carries the same exposure.

Now drug manufacturers are making the same argument — in state court

The August 2026 Lilly filings are worth understanding in detail, because the legal theory is new and it changes who can come after a peptide seller.

Lilly filed six complaints on August 12, 2026, all over retatrutide, against what its announcement describes as compounding pharmacies, medical spas, and online sellers claiming research-use-only status.^[13] The core allegation is the same one federal prosecutors made: that "research use only" is a pretext, and that the defendants are in fact selling an unapproved new drug for human use.

What is unusual is how Lilly pleads it. There is no Lanham Act count and no patent count. Instead the complaints plead state consumer-protection and unfair-competition claims across eight states, each built on a state analogue of the federal ban on selling unapproved new drugs — for example, Texas Health & Safety Code § 431.114(a) and Colorado Revised Statutes § 12-280-131(1).^[14] The relief sought is a permanent injunction against marketing, distributing, or selling anything containing or purporting to contain retatrutide.

Why that matters practically: a private company does not need FDA to act first. Individual states' drug statutes give manufacturers a direct route into court against sellers that federal enforcement has not reached. Lilly also went outside the courts, publicly pressing marketplaces and payment processors to cut sellers off — a distribution-layer squeeze that does not require winning a case at all.

These are newly filed complaints. There has been no ruling, no injunction, and no settlement, and no defendant has been found liable. But the filings tell you where enforcement pressure is heading.

Regulators outside the US are converging on the same targets

Two international actions in the same window point the same way:

• UK. On July 24, 2026 the MHRA issued a public warning about buying GLP-1 medicines from unregulated online sources and specifically named retatrutide, stating that it is not approved for UK use and that "anyone selling this product is doing so illegally."^[16]
• Canada. On July 29, 2026 Health Canada announced that the Superior Court of Québec had granted a permanent injunction against Canlab Research, barring it from manufacturing, testing, distributing, or selling unauthorized injectable peptides in Canada — and from advertising them on any website or social account reachable from a Canadian IP address. The injunction itself was granted June 11, 2026. No individual peptides are named in the release.^[17]

The quality problem underneath

Enforcement actions do not happen in a vacuum. There is a real quality problem in the gray-market supply chain, and it is worth being careful about how we describe it — because the strongest evidence is not a testing statistic. It is the court record.

What the Paradigm case established. Federal investigators determined that many products advertised, labeled, and sold as SARMs in fact contained testosterone.^[2] Kawa also admitted to forging the laboratory certificates customers used to verify purity.^[3] These are findings in a federal criminal case, not estimates. They are also more useful than any purity number, because they tell you something a purity number cannot: the document you were checking could itself be the fraud.

What the FDA has documented directly. FDA has received multiple reports of adverse events, some requiring hospitalization, tied to dosing errors with compounded injectable semaglutide — patients and clinicians measuring the wrong dose from products that arrive in unfamiliar concentrations.^[9]

What independent testing can and cannot tell you. Finnrick, a service that sends customer-submitted vials to partner labs and publishes the results, reported in February 2026 that 8% of samples across 140 endotoxin tests through January 2026 showed endotoxin above trace amounts.^[7] That figure comes with a caveat Finnrick supplies itself: endotoxin is a paid add-on, ordered mostly by buyers who already suspected a problem. The sample is self-selected, so it describes suspicious vials rather than the market as a whole. Read it as a signal that the problem is real, not as a contamination rate.

For anyone trying to evaluate product quality, learning to read a Certificate of Analysis is still worth the effort — with Paradigm as the reminder of its limit. Our COA verification guide walks through the process step by step, and our COA checker tool can help you spot red flags.

What's driving the crackdown

Several forces have converged to produce this enforcement wave.

The GLP-1 market explosion. The success of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) created a multi-billion-dollar market virtually overnight. When compounding pharmacies and gray-market vendors began selling cheaper alternatives, the economic stakes became large enough to attract serious regulatory and legal attention.^[9]

Political pressure. Safety incidents — including hospitalizations tied to dosing errors with compounded injectables — have generated media scrutiny and pressure on the FDA to demonstrate it is protecting consumers.^[9]

Pharmaceutical industry interest. Companies like Novo Nordisk and Eli Lilly have invested heavily in litigation to protect their branded products from compounded and gray-market competition. The 132 Novo complaints and the six Lilly filings represent a private-sector enforcement effort that parallels and reinforces the government's actions.^[5][13]

Documented failures on the record. Adverse-event reports and court findings give the agency concrete grounds rather than abstract regulatory theory: dosing errors requiring hospitalization, products sold as SARMs that contained testosterone, and forged purity documentation.^[3]

The combination of these factors means the current enforcement wave is not a temporary crackdown that will ease once attention moves elsewhere. The structural incentives — economic, political, and safety-related — all point in the same direction.

What this means for you

If you have been sourcing peptides from gray-market vendors, here is a clear-eyed assessment of where things stand.

Don't panic. The peptides you already have don't change because a vendor shut down or a prosecution was announced. If you've been using a product without adverse effects, nothing about the enforcement landscape changes your immediate situation.

Understand the trend. The gray-market model for peptide sales is contracting. Vendors are shutting down, being prosecuted, or facing lawsuits. The remaining vendors operate under the same legal exposure as those that have already been taken down. This is not a temporary dip — it is a structural shift.

Shift toward legitimate channels. Compounding pharmacies that operate under USP standards and source FDA-registered APIs provide a fundamentally different level of quality assurance. With a valid prescription from a licensed provider, many peptides can be legally compounded today. Telehealth platforms have made this accessible nationwide.

Do not read the July PCAC vote as a green light. On July 23-24, 2026 an FDA advisory committee recommended six peptides — including BPC-157, KPV, and TB-500 — for the 503A Bulks List. FDA has taken no action on that recommendation, so none of them became legal to compound. Enforcement risk for gray-market sellers is unchanged by the vote. See our July 2026 PCAC hub for the full picture.

Watch the private-litigation channel, not just FDA. The most consequential enforcement development of this summer did not come from a regulator. If you are buying investigational compounds like retatrutide from a research-use-only vendor, the realistic near-term risk to your supply is a manufacturer lawsuit, a payment processor cutting the seller off, or a border detention under Import Alert 66-80 — not an FDA warning letter.

---

References

1. [1]

   U.S. Attorney's Office, Eastern District of Kentucky. “Nicholasville Compounding Pharmacy and its Owner Plead Guilty to Unlawful Distribution.” 2020. Link

   DOJ press release, October 29, 2020. Tailor Made Compounding LLC of Nicholasville, Kentucky and its owner Jeremy Delk pleaded guilty; the pharmacy agreed to forfeit $1,788,906.82. A companion release covers the February 2021 sentencing.

2. [2]

   U.S. Department of Justice. “United States v. Matthew Kawa, et al. (Paradigm Peptides), N.D. Indiana.” 2025. Link

   DOJ case page for the prosecution of a prominent gray-market peptide vendor. Guilty pleas entered December 10, 2025. The page's stated theory is mislabeled SARMs that in fact contained testosterone, plus unapproved new drugs.

3. [3]

   U.S. Attorney's Office, Northern District of Indiana. “Illinois Man and Indiana Woman Sentenced Respectively to 70 Months and 16 Months in Prison For Selling Unapproved Drugs in Interstate Commerce.” 2026. Link

   DOJ press release announcing the July 30, 2026 sentencing in the Paradigm Peptides case.

4. [4]

   U.S. Food and Drug Administration. “Warning Letter — GLP-1 Solution, Inc. (MARCS-CMS 715883), issued September 9, 2025.” 2025. Link

   One of 58 warning letters issued the same day under the subject 'Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth).' Recipients were telehealth companies, online sellers, and med spas. We found no single FDA page consolidating all 58; the count comes from FDA's warning-letter database.

5. [5]

   Novo Nordisk. “Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded 'semaglutide'.” 2025. Link

   Company announcement, August 2025, reporting 132 complaints filed across 40 states. These are state-law deceptive-marketing, consumer-fraud, and unfair-competition claims. Company statement; allegations have not been proven.

6. [6]

   Finnrick. “Independent peptide testing and vendor safety rankings.” 2026. Link

   Free-testing service that brokers customer-submitted samples to commercial partner labs for analysis, then publishes vendor ratings. It is not itself a laboratory and is not ISO 17025 accredited. Its database updates continuously, so any figure drawn from it needs a retrieval date. Retrieved August 15, 2026.

7. [7]

   Finnrick. “Why Endotoxin Testing Matters for Peptides.” 2026. Link

   Published February 6, 2026. Reports that 8% of samples across 140 endotoxin tests through January 2026 showed quantifiable endotoxin above trace amounts. Endotoxin is a paid add-on, so the sample is self-selected toward products buyers already suspected.

8. [8]

   U.S. Food and Drug Administration. “Regulations Regarding "Intended Uses", Final Rule, 86 Fed. Reg. 41383 (Aug. 2, 2021).” 2021. Link

   Final rule codified at 21 C.F.R. §§ 201.128 and 801.4. Establishes that a product's intended use may be shown by 'any relevant source,' including labeling, advertising, and the circumstances of distribution.

9. [9]

   U.S. Food and Drug Administration. “FDA's concerns with unapproved GLP-1 drugs used for weight loss.” 2025. Link

   FDA safety communication documenting adverse events from compounded semaglutide and tirzepatide, including dosing errors requiring hospitalization.

10. [10]

    Grips Intelligence. “Peptide Sciences retailer traffic and transaction estimates.” 2026. Link

    Third-party retailer analytics platform providing estimated revenue and transaction data for e-commerce brands. The $7.45M figure is a December 2025 monthly snapshot. Historical monthly data sits behind a login, so the number is an estimate we could not independently confirm.

11. [11]

    U.S. Food and Drug Administration. “FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs.” 2026. Link

    FDA compliance guidance for telehealth companies marketing compounded drugs, including warning-letter waves over misbranding of compounded GLP-1 products.

12. [12]

    STAT (Pharmalot). “HHS asks Justice Department to probe Hims & Hers over its cheaper compounded version of Wegovy.” 2026. Link

    Ed Silverman, STAT/Pharmalot, February 6, 2026. Reports HHS's referral of Hims & Hers to the DOJ over its compounded oral semaglutide plan, sourced to a social media post by HHS general counsel Mike Stuart.

13. [13]

    Eli Lilly and Company. “Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market.” 2026. Link

    Company statement, August 12, 2026, announcing six lawsuits over retatrutide and calling on marketplaces and payment processors to de-platform sellers.

14. [14]

    Eli Lilly & Co. v. Lone Star Peptide Co. LLC. “Complaint, No. 4:26-cv-06562 (S.D. Tex. Aug. 12, 2026), ECF 1.” 2026. Link

    One of six complaints filed the same day. Pleads state consumer-protection and unfair-competition claims predicated on state analogues of the federal bar on unapproved new drugs. No Lanham Act count and no patent count. These are allegations; no defendant has been found liable.

15. [15]

    U.S. Food and Drug Administration. “Import Alert 66-80: Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances.” 2026. Link

    Republished August 13, 2026. Authorizes detention of foreign-sourced GLP-1 APIs except for green-listed firm/product pairs. The August revision expanded scope — adding an orforglipron product code and four Hormone N.E.C. codes — and updated the green-listing guidance. Product-code scope reaches peptide APIs for prescription compounding and entries keyed to the word 'Retatrutide.'

16. [16]

    Medicines and Healthcare products Regulatory Agency (UK). “No summer shortcut for safe weight loss.” 2026. Link

    MHRA public warning, 24 July 2026. Specifically flags retatrutide as not approved for UK use and states that anyone selling it is doing so illegally.

17. [17]

    Health Canada. “Health Canada obtains permanent injunction preventing Canlab Research's illegal sale of injectable peptides in Canada.” 2026. Link

    Announced July 29, 2026; the Superior Court of Quebec granted the injunction June 11, 2026. Bars manufacturing, testing, distributing, selling, or advertising unauthorized injectable peptides in Canada. No individual peptides are named in the release.

---

---

Related content

News

What Happened to Peptide Sciences

A detailed look at the largest gray-market vendor shutdown.

Guide

How to Verify a Certificate of Analysis

Learn to evaluate peptide quality documentation.

Tool

COA Checker

Evaluate a Certificate of Analysis for red flags.

Peptide

BPC-157

The most popular gray-market research peptide. Full evidence profile and regulatory status.

News

Paradigm Peptides Sentencing

The owner of a major peptide vendor was sentenced to 70 months in July 2026. What he was actually convicted of.